AMG 570

Drug Profile

AMG 570

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Amgen
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 01 Mar 2016 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in USA (Parenteral) (NCT02618967)
  • 09 Dec 2015 Preclinical trials in Systemic lupus erythematosus in USA (Parenteral) before December 2015
  • 09 Dec 2015 Amgen plans a first-in-human phase I trial in Healthy volunteers in USA (SC) (NCT02618967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top